Enoxaparin

Enoxaparin is a low-molecular-weight heparin (LMWH), made by chemically breaking unfractionated heparin, derived from pig intestinal mucosa, into shorter polysaccharide chains. Compared with standard unfractionated heparin, these shorter chains give more consistent, predictable anticoagulation, a longer duration of action, and reliable absorption after injection under the skin, so fixed weight-based doses can usually be given without frequent laboratory monitoring.

Enoxaparin is used to prevent venous thromboembolism (clots in the deep veins and lungs) in hospitalized and surgical patients, to treat established deep-vein thrombosis and pulmonary embolism, and in the management of acute coronary syndromes, including unstable angina and heart attack. In acutely ill medical patients confined to bed, the MEDENOX trial showed that enoxaparin markedly reduced the risk of venous thromboembolism compared with placebo ^[3].

In acute coronary syndromes, enoxaparin was compared head-to-head with unfractionated heparin. The ESSENCE trial found that enoxaparin lowered the combined rate of death and cardiac events in patients with unstable angina or non-Q-wave myocardial infarction ^[1], and the larger EXTRACT-TIMI 25 trial showed that enoxaparin was superior to unfractionated heparin in patients receiving clot-dissolving (fibrinolytic) therapy for ST-elevation heart attack, at the cost of a modest increase in major bleeding ^[2].

The chief risk of enoxaparin, as with all anticoagulants, is bleeding; other concerns include a fall in platelet counts (heparin-induced thrombocytopenia, less common than with unfractionated heparin) and accumulation in people with poor kidney function, since the drug is cleared by the kidneys. It is given by subcutaneous injection, and sometimes intravenously, and is available as the brand Lovenox and as generic or biosimilar versions ^[1][2].

Enoxaparin is prescription only and given by injection. The main risk is bleeding, from minor bruising at the injection site to serious internal hemorrhage. It can lower platelets, and although less often than unfractionated heparin it can still trigger heparin-induced thrombocytopenia, a paradoxical clotting reaction. Long-term use may weaken bone. It carries a boxed warning about spinal or epidural hematoma when used around neuraxial anesthesia or spinal puncture, which can cause lasting paralysis. Combining it with antiplatelet drugs, NSAIDs, or other anticoagulants raises bleeding risk. Because it is cleared by the kidneys, doses must be lowered in significant kidney impairment. Protamine sulfate only partially reverses its effect.

Enoxaparin is a low molecular weight heparin cleared by desulfation and the kidney, with no cytochrome metabolism, so every interaction that matters is pharmacodynamic and about bleeding.

Anything else that impairs hemostasis adds directly to its effect: aspirin and other NSAIDs, clopidogrel and the other P2Y12 inhibitors, glycoprotein IIb/IIIa antagonists, thrombolytics, warfarin, direct oral anticoagulants and dextran. Because enoxaparin is followed by anti-Xa activity rather than a routine coagulation test, the added risk is often invisible until bleeding declares itself.

One specific hazard carries a boxed warning. In someone receiving neuraxial anesthesia or undergoing spinal puncture, enoxaparin raises the risk of spinal or epidural hematoma, which can cause lasting paralysis; an indwelling epidural catheter, repeated or traumatic punctures, spinal deformity and concurrent antiplatelet or anticoagulant drugs each compound it. Heparins also suppress aldosterone, so pairing enoxaparin with ACE inhibitors, ARBs or potassium-sparing diuretics can push potassium up, especially alongside kidney impairment or diabetes.

Checking a whole stack? Run it through interactions + stacks.

Enoxaparin was among the first of the low-molecular-weight heparins, a class created by chemically depolymerizing standard heparin into shorter, more uniform fragments to obtain a more predictable anticoagulant. It was developed in France and brought to market by the company that would become part of Sanofi, receiving United States Food and Drug Administration approval in 1993 under the brand name Lovenox, known as Clexane in much of the rest of the world.

The rationale grew out of the realization that unfractionated heparin, though effective, bound unpredictably to plasma proteins and cells and therefore required frequent laboratory monitoring. By favoring inhibition of factor Xa over thrombin and binding less avidly to other targets, enoxaparin delivered a more consistent dose-response and allowed convenient subcutaneous injection. A large body of clinical trials across deep-vein thrombosis, pulmonary embolism, and acute coronary syndromes followed, and enoxaparin now appears on the World Health Organization's List of Essential Medicines.

Enoxaparin is one of the best-established injectable anticoagulants in medicine, valued for combining reliable clot prevention with the practical convenience of fixed, weight-based dosing that usually needs no routine blood testing. Its evidence base spans surgical thromboprophylaxis, the treatment of established venous clots, and the management of heart attacks, making it a familiar presence on hospital wards and in outpatient care alike.

A meta-analysis of tens of thousands of patients with acute coronary syndromes found it superior to unfractionated heparin for preventing death or myocardial infarction, a result frequently cited in its favor. The honest counterpoint is that, like any effective blood thinner, it raises the risk of bleeding, and it must be used cautiously in patients with impaired kidney function since it is cleared renally. Balanced against these considerations, its predictability and strong track record have made it a durable standard against which newer anticoagulants are often measured.